Tags : Aprinoia

Celgene Licenses Aprinoia’s APN-1607 an Imaging Tracer, for Neurodegenerative Diseases

Shots: Celgene to get non-exclusive rights for Aprinoia’s bAPN-1607 and Aprinoia to receive license and usage fee annually The focus of the agreement is utilize Aprinoia’s APN-1607 in developing therapies by understanding tau pathology in rare tauopathies including Alzheimer’s Disease APN-1607 is [18F]-labeled PET imaging tracer, enabling to visualize tau pathology in diverse tauopathies, MCI, […]Read More